https://kstockbriefing.com
![[Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) (Correction) / 2025-08-06](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환셀트리온.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has issued a corrected provisional earnings release for Q2 2025 on a consolidated basis, populating previously omitted net income metrics including Q2 net profit of KRW 63.3B and controlling interest net profit of KRW 61.2B. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has been selected as the preferred bidder and executed an exclusive negotiation commitment with an undisclosed global company to acquire a firm possessing US cGMP active pharmaceutical ingredient (API) manufacturing facilities. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to dispose of 7,043 common treasury shares (approx. KRW 1.03B) to grant shares following the exercise of stock options by employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Treasury Share Delivery Completion and Shareholding…
Read More “[Disclosure] Celltrion (068270) – Decision on Disposal of Treasury Shares / 2025-07-23” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its provisional Q2 2025 consolidated performance, reporting revenue of KRW 1.2899T, operating profit of KRW 475.6B, and net profit of KRW 324.4B. Year-over-year, revenue and operating profit grew by 11.50% and 9.46% respectively, with cumulative Q2 revenue reaching KRW 2.5882T (+23.02% YoY)….
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a corrected disclosure revising its FY2025 consolidated revenue guidance upward from KRW 5.5705T (midpoint of +20% to +25% YoY growth range) to KRW 5.7978T (midpoint of +25% to +30% YoY growth range). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is additionally listing 8,494,384 common shares on July 25, 2025, following a bonus issue. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Execution on Scheduled Date (July 25, 2025) This disclosure details the additional listing…
Read More “[Disclosure] Celltrion (068270) – Additional Listing (Bonus Issue) / 2025-07-22” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported Q2 2025 consolidated revenue of KRW 961.5B (+9.91% YoY) and operating profit of KRW 242.5B (+234.49% YoY). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Confirmed Results and Q2 2025 Earnings Release Disclosure This filing provides…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire 554,632 common treasury shares (approx. KRW 100.0B) through open market purchases to stabilize share prices and enhance shareholder value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Open-Market Buyback Execution and Periodic Holdings…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed that the Supreme Court (court of third instance) dismissed the prosecution’s appeal regarding alleged violations of accounting standards, rendering a not-guilty verdict. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Supreme Court Appeal Dismissal and…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a corrected disclosure confirming that the Supreme Court dismissed the prosecution’s appeal regarding alleged violations of accounting standards, finalizing a not-guilty verdict, and updated the filing upon receipt of the official written judgment. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…